# US 2012/0252747 A1 · Macrocyclic compounds and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252747 A1
- Document ID: US20120252747A1
- Status: Published application
- Kind: A1
- Application number: 13/525,900
- Filed: 2012-06-18
- Published: 2012-10-04
- Earliest claimed: 2004-02-27
- Assignees: Melinta Therapeutics, Inc.
- Inventors: Jay J. Farmer; Ashoke Bhattacharjee; Yi Chen; Joel A. Goldberg; Joseph A. Ippolito; Zoltan F. Kanyo; Rongliang Lou; Adegboyega K. Oyelere; Edward C. Sherer; Joyce A. Sutcliffe; Deping Wang; Yusheng Wu; Yanming Du
- Web page: https://patentgrep.com/patent/US20120252747A1

## CPC

- C07H 17/08: Hetero rings containing eight or more ring members, e.g. erythromycins
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/10: Laxatives
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07H 17/00: Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides macrocyclic compounds useful as therapeutic agents of the formula: or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof, wherein T, R1, R2, R3, D, E, F, and G are as defined herein. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents.

## Claims

### Claim 1

A compound having the formula:
or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof,
wherein
T is a 14-, 15-, or 16-membered macrolide connected via a macrocyclic ring carbon atom;
R1 and R3 independently are selected from the group consisting of: (a) H, (b) a C1-6 alkyl group, (c) a C2-6 alkenyl group, (d) a C2-6 alkynyl group, (e)—C(O)R5, (f) —C(O)OR5, (g) —C(O)—NR4R4, (h) —C(S)R5, (i) —C(S)OR5, (j) —C(O)SR5, and (k) —C(S)NR4R4;
R2 is hydrogen or —OR12;
D is selected from the group consisting of:
(a) a single bond, (b) a C1-6 alkyl group, (c) a C2-6 alkenyl group, (d) a C2-6 alkynyl group, (e) —C(O)—X—, (f) —C(O)O—X—, (g) —C(O)NR4R4—X—,
(h) —C(═NR4)—X—, (i) —C(═NR4)O—X—, (j) —C(═NR4)N—X—,
(k) —SO2—X—, (l) —C(NR4)NR4—X—, (m) —C(S)—X—,
(n) —C(S)NR4—X—, (o) —C(NR4)S—X—, or (p) —C(O)S—X—, wherein
i) 0-2 carbon atoms in any of (b)-(d) of D immediately above optionally is replaced by a moiety selected from the group consisting of O, S(O)p, and NR4,
ii) each of the groups (b)-(d) immediately above optionally is substituted with one or more R5 groups,
iii) alternatively when R5 is present as an optional substituent on (b)-(d), R3 and R5 can be taken together with the atoms to which they are attached to form a 3-7 membered ring, and
iv) X is selected from the group consisting of (aa) a C1-6 alkyl group, (bb) a C2-6 alkenyl group, and (cc) a C2-6 alkynyl group, wherein each of groups (aa)-(cc) optionally is substituted with one or more R5 groups;
F is selected from the group consisting of:
(a) a single bond, (b) a C1-6 alkyl group, (c) a C2-6 alkenyl group, and (d) a C2-6 alkynyl group, wherein
i) 0-2 carbon atoms in any of (b)-(d) of F immediately above optionally is replaced by a moiety selected from the group consisting of O, S(O)p, and NR4,
ii) any of (b)-(d) of F immediately above optionally is substituted with one or more R5 groups, and
iii) any of (b)-(d) of F immediately above optionally is substituted with C1-6 alkyl-R5 groups;
E is selected from the group consisting of:
(a) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
(b) a 3-10 membered saturated, unsaturated, or aromatic carbocycle,
(c) a —W-[3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur],
(d) a —W-[3-10 membered saturated, unsaturated, or aromatic carbocycle],
(e) —C(O)—, (l) —C(O)O—, (g) —C(O)NR4—, (h) —C(═NR4)—,
(i) —C(═NR4)O—, (j) —C(═NR4)NR4—, (k) —OC(O)—, (l) —OC(O)O—,
(m) —OC(O)NR4—, (n) —NR4C(O)—, (o) —NR4C(O)O—,
(p) —NR4C(O)NR4—, (q) —NR4C(═NR4)NR4—, (r) —S(O)p—,
(s) —NR4S(O)2—, (t) —S(O)2NR4—, (u) —C(N—OR4)—, (v) —CH2—,
(w) —C(N—NR4R4)—, (x) —C(S)NR4—, (y) —NR4C(S)—, (z) —C(S)O—, or
(aa) —OC(S)—, wherein
i) any of (a)-(d) immediately above optionally is substituted with one or more R5 groups; and
ii) W is selected from the group consisting of:
(aa) —OCO—, (bb) —OC(O)O—, (cc) —OC(O)NR4—,
(dd) —NR4C(O)O—, (ee) —OCNOR4—,
(ff) —NR4—C(O)O—, (gg) —C(S)(NR4)—, (hh) —NR4—,
(ii) —OC(S)O—, (jj) —OC(S)NR4—, (kk) —NR4C(S)O—, (ll) —OC(S)NOR4—, (mm) —C(S)O—, (nn) -, OC(S)—, (oo) —C(O)—, (pp) —C(O)O—, (qq) —C(O)NR4—, (rr) —C(═NR4)—,
(ss) —C(═NR4)O—, (tt) —C(═NR4)NR4—, (uu) —OC(O)—, (vv) —OC(O)O—, (ww) —OC(O)NR4—, (xx) —NR4C(O)—, (yy) —NR4C(O)O—,
(zz) —NR4C(O)NR4—, (aaa) —NR4C(═NR4)NR4—, (bbb) —S(O)p—, (ccc) —NR4S(O)2—, (ddd) —S(O)2NR4—, (eee) —C(N—OR4)—, (fff) —C(N—NR4R4)—, (ggg) —C(S)NR4—, or (hhh) —NR4C(S)—;
G is selected from the group consisting of: (a) B′ and (b) B′—Z—B″, wherein
i) each B′ and B″ is independently selected from the group consisting of (aa) an aryl group, (bb) a heteroaryl group, (cc) a biaryl group, (dd) a fused bicyclic or tricyclic saturated, unsaturated or aromatic ring system optionally containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (ee) a 3-10 membered saturated or unsaturated heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (ff) a 3-10 membered saturated, or unsaturated carbocycle, wherein each (aa)-(ff) optionally is substituted with one or more R11 groups; and
ii) Z is selected from the group consisting of:
(aa) a single bond, (bb) a C1-2 alkyl group, (cc) a C2 alkenyl group,
(dd) a C2 alkynyl group, (ee) —C(O)—, (ff) —C(O)O—, (gg) —C(O)NR4—,
(hh) —C(═NR4)—, (ii) —C(═NR4)O—, (jj) —C(═NR4)NR4—, (kk) —S(O)p—,
(ll) —OC(O)—, (mm) —C(S)—, (nn) —C(S)NR4—, (O) —C(NR4)S—, (pp) —C(O)S—, (qq) —O—, (rr) —NR4—, (ss) —NR4C(O)—, (tt) —OC(NR4)—, (uu) —NC(NR4)—, (vv) —C(S)O—, (ww) —SC(O)—, and (xx) —OC(S)—;
R4, at each occurrence, independently is selected from the group consisting of:
(a) H, (b) a C1-6 alkyl group, (c) a C2-6 alkenyl group, (d) a C2-6 alkynyl group, (e) a C6-10 saturated, unsaturated, or aromatic carbocycle, (f) a 3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (g)—C(O)—C1-6 alkyl, (h) —C(O)—C2-6 alkenyl, (i) —C(O)—C2-6 alkynyl, (j)—C(O)—C6-10 saturated, unsaturated, or aromatic carbocycle, (k) —C(±)-3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (l) —C(O)O—C1-6 alkyl, (m) —C(O)O—C2-6 alkenyl, (n) —C(O)O—C2-6 alkynyl,
(o) —C(O)O—C6-10 saturated, unsaturated, or aromatic carbocycle, p) —C(O)O-3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and
q) —C(O)NR6R6,
wherein any of (b)-(p) optionally is substituted with one or more R5 groups;
alternatively, NR4R4 forms a 3-7 membered saturated, unsaturated or aromatic ring including the nitrogen atom to which the R4 groups are bonded, wherein said ring is optionally substituted at a position other than the nitrogen atom to which the R4 groups are bonded, with one or more moieties selected from the group consisting of O, S(O)p, N, and NRB;
R5 is selected from the group consisting of:
(a) R7, (b) a C1-8 alkyl group, (c) a C2-8 alkenyl group, (d) a C2-8 alkynyl group, (e) a C3-12 saturated, unsaturated, or aromatic carbocycle, and (f) a 3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, or two R5 groups, when present on the same carbon atom can be taken together with the carbon atom to which they are attached to form a spiro 3-6 membered carbocyclic ring or heterocyclic ring containing one or more heteroatoms selected form the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (b)-(f) immediately above optionally is substituted with one or more R7 groups;
R6, at each occurrence, independently is selected from the group consisting of:
(a) H, (b) a C1-6 alkyl group, (c) a C2-6 alkenyl group, (d) a C2-6 alkynyl group, (e) a C3-10 saturated, unsaturated, or aromatic carbocycle, and (f) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (b)-(f) optionally is substituted with one or more moieties selected from the group consisting of:
(aa) a carbonyl group, (bb) a formyl group, (cc) F, (dd) Cl, (ee) Br, (ff) I, (gg) CN, (hh) NO2, (ii)-OR8,
(jj) —S(O)pR8, (kk) —C(O)R8, (ll) —C(O)OR8,
(mm) —OC(O)R8, (nn) —C(O)NR8R8,
(oo) —OC(O)NR8R8, (pp) —C(═NR8)R8,
(qq) —C(R8)(R8)OR8, (rr) —C(R8)2OC(O)R8,
(ss) —C(R8)(OR8)(CH2)rNR8R8, (tt) NR8R8,
(uu) —NR8OR8, (vv) —NR8C(O)R8,
(ww) —NR8C(O)OR8, (xx) —NR8C(O)NR8R8,
(yy) —NR8S(O)rR8, (zz) —C(OR8)(OR8)R8,
(ab) —C(R8)2NR8R8, (ac) ═NR8,
(ad) —C(S)NR8R8, (ae) —NR8C(S)R8,
(af) —OC(S)NR8R8, (ag) —NR8C(S)OR8,
(ah) —NR8C(S)NR8R8, (ai) —SC(O)R8,
(aj) a C1-8 alkyl group, (ak) a C2-8 alkenyl group, (al) a C2-8 alkynyl group, (am) a C1-8 alkoxy group, (an) a C1-8 alkylthio group, (ao) a C1-8 acyl group, (ap) —CF3,
(aq) —SCF3, (ar) a C3-10 saturated, unsaturated, or aromatic carbocycle, and (as) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
alternatively, NR6R6 forms a 3-10 membered saturated, unsaturated or aromatic ring including the nitrogen atom to which the R6 groups are attached wherein said ring is optionally substituted at a position other than the nitrogen atom to which the R6 groups are bonded, with one or more moieties selected from the group consisting of O, S(O)p, N, and NR8;
alternatively, CR6R6 forms a carbonyl group;
R7, at each occurrence, is selected from the group consisting of:
(a) H, (b) ═O, (c) F, (d) Cl, (e) Br, (f) I, (g) —CF3,
(h) —CN, (i) —N3, (j) —NO2, (k) —NR6(CR6R6)tR9, (l) —OR9, (m) —S(O)pC(R6R6)tR9,
(n) —C(O)(CR6R6)tR9, (o) —OC(O)(CR6R6)tR9, (p) —SC(O)(CR6R6)tR9, (q) —C(O)O(CR6R6)tR9, (r) —NR6C(O)(CR6R6)tR9, (s) —C(O)NR6(CR6R6)tR9, (t) —C(═NR6)(CR6R6)tR9, (u) —C(═NNR6R6)(CR6R6)tR9, (v) —C(═NNR6C(O)R6)(CR6R6)tR9, (w) —C(═NOR9)(CR6R6)tR9, (x) —NR6C(O)O(CR6R6)tR9, (y) —OC(O)NR6(CR6R6)tR9, (z) —NR6C(O)NR6(CR6R6)tR9,
(aa) —NR6S(O)p(CR6R6)tR9, (bb) —S(O)pNR6(CR6R6)tR9, (cc) —NR6S(O)pNR6(CR6R6)tR9, (dd) —NR6R6, (ee) —NR6(CR6R6), (ff) —OH, (gg) —NR6R6, (hh) —OCH3, (ii) —S(O)pR6, (jj) —NC(O)R6, (kk) a C1-6 alkyl group, (ll) a C2-6 alkenyl group, (mm) a C2-6 alkynyl group, (nn) —C3-10 saturated, unsaturated, or aromatic carbocycle, and (oo) 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (kk)-(oo) optionally is substituted with one or more R9 groups;
alternatively, two R7 groups form —O(CH2)uO—;
R8 is selected from the group consisting of:
(a) R5, (b) H, (c) a C1-6 alkyl group, (d) a C2-6 alkenyl group, (e) a C2-6 alkynyl group,
(f) a C3-10 saturated, unsaturated, or aromatic carbocycle, (g) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (h) —C(O)—C1-6 alkyl, (i) —C(O)—C1-6 alkenyl, (j) —C(O)—C1-6 alkynyl, (k) —C(O)—C3-10 saturated, unsaturated, or aromatic carbocycle, and (l) —C(O)-3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (c)-(k) optionally is substituted with one or more moieties selected from the group consisting of: (aa) H, (bb) F, (cc) Cl, (dd) Br, (ee) I, (ff) CN, (gg) NO2, (hh) OH, (ii) NH2, (jj) NH(C1-6 alkyl), (kk) N(C1-6 alkyl)2, (ll) a C1-6 alkoxy group, (mm) an aryl group, (nn) a substituted aryl group, (O) a heteroaryl group, (pp) a substituted heteroaryl group, and qq) a C1-6 alkyl group optionally substituted with one or more moieties selected from the group consisting of an aryl group, a substituted aryl group, a heteroaryl group, a substituted heteroaryl group, F, Cl, Br, I, CN, NO2, CF3, SCF3, and OH;
R9, at each occurrence, independently is selected from the group consisting of:
(a) R10, (b) a C1-6 alkyl group, (c) a C2-6 alkenyl group, (d) a C2-6 alkynyl group, e) a C3-10 saturated, unsaturated, or aromatic carbocycle, and f) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (b)-(f) optionally is substituted with one or more R10 groups;
R10, at each occurrence, independently is selected from the group consisting of:
(a) H, (b) ═O, (c) F, (d) Cl, (e) Br, (f) I, (g) —CF3, (h) —CN, (i) —NO2, (j) —NR6R6, (k) —OR6, (l) —S(O)pR6, (m) —C(O)R6, (n) —C(O)OR6, (o) —OC(O)R6, (p) NR6C(O)R6, (q) —C(O)NR6R6, (r) C(═NR6)R6, (s) —NR6C(O)NR6R6, (t) —NR6S(O)pR6, (u) —S(O)pNR6R6, (v) —NR6S(O)pNR6R6, (w) a C1-6 alkyl group, (x) a C2-6 alkenyl group, (y) a C2-6 alkynyl group, (z) a C3-10 saturated, unsaturated, or aromatic carbocycle, and (aa) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (w)-(aa) optionally is substituted with one or more moieties selected from the group consisting of R6, F, Cl, Br, I, CN, NO2, —OR6, —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, a C1-6 alkoxy group, a C1-6 alkylthio group, and a C1-6 acyl group;
R11 each occurrence, independently is selected from the group consisting of:
(a) a carbonyl group, (b) a formyl group, (c) F, (d) Cl, (e) Br, (f) I, (g) CN, (h) NO2, (i) OR8, (j) —S(O)pR8, (k) —C(O)R8, (l) —C(O)OR8, (m) —OC(O)R8, (n) —C(O)NR8R8, (o) —OC(O)NR8R8, (p) —C(═NR8)R8, (q) —C(R8)(R8)OR8, (r) —C(R8)2OC(O)R8, (s) —C(R8)(OR8)(CH2)rNR8R8, (t) —NR8R8, (u) —NR8OR8, (v) —NR8C(O)R8, (w) —NR8C(O)OR8, (x) NR8C(O)NR8R8, (y) NR8S(O)rR8, (z) —C(OR8)(OR8)R8, (aa) —C(R8)2NR8R8, (bb) ═NR8, (cc) —C(S)NR8R8, (dd) —NR8C(S)R8, (ee) —OC(S)NR8R8, (ff) —NR8C(S)OR8, (gg) —NR8C(S)NR8R8, (hh) —SC(O)R8, (ii) a C1-8 alkyl group, (jj) a C2-8 alkenyl group, (kk) a C2-8 alkynyl group, (ll) a C1-8 alkoxy group, (mm) a C1-8 alkylthio group, (nn) a C1-8 acyl group, (oo) a C3-10 saturated, unsaturated, or aromatic carbocycle, and (pp) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein (ii)-(kk) optionally are substituted with one or more R5 groups;
R12 is selected from the group consisting of:
(a) H, (b) a C1-6 alkyl group, (c) a C2-6 alkenyl group, (d) a C2-6 alkynyl group, (e) —C(O)R5, (f) —C(O)OR5, (g) —C(O)—NR4R4, (h) —C(S)R5, (i) —C(S)OR5, (j) —C(O)SR5, (k) —C(S)—NR4R4, (l) a C3-10 saturated, unsaturated, or aromatic carbocycle, or (m) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (n) a —(C1-6 alkyl) —C3-10 saturated, unsaturated, or aromatic carbocycle, and (O) a —(C1-6 alkyl)-3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein (a)-(d) and (l)-(o) optionally are substituted with one or more R5 groups;
p at each occurrence is 0, 1, or 2;
r at each occurrence is 0, 1, or 2;
t at each occurrence is 0, 1, or 2;
u at each occurrence is 1, 2, 3, or 4;
provided that
i) when T is a 14 or 15 membered macrolide D-E is not
ii) when T is a 14 or 15 membered macrolide F—B′ is not
iii) when T is a 14 or 15 membered macrolide B′—Z—B″ is not
iv) when T is a 14 or 15 membered macrolide R11 is not
v) when the compound has formula I and T is
D is not a single bond or a —CH2—,
vi) when the compound has formula I and T is a 14 or 15 membered macrolide -D-E-F- is not a —CH2—,
vii) when the compound has formula I and T is a 14 or 15 membered macrolide D E F G is not a chemical moiety selected from the chemical moieties listed in Table A
TABLE A
and
viii) when the compound has formula II and T is a 16 membered macrolide
i. -D-E- is not a glycoside attached via its anomeric carbon,
ii. -D-E-F-G is not a C1-4 (alkyl), C2-4(alkenyl), or C2-4(alkynyl) chain bonded to a 5-10 membered monocyclic or bicyclic carbocyle or heterocycle or bonded to a 5 or 6 membered carbocycle or heterocycle further bonded to a 5 or 6 membered carbocycle or heterocycle, any of said carbocycles or heterocycles being optionally substituted with one or more groups selected from the group consisting of (aa) —OH, (bb) —F, (cc) —Cl, (dd) —I, and (ee) —NO2, and
iii. -D-E-F-G- is not a chemical moiety selected from the chemical moieties listed in Table B
TABLE B
-(t-butoxycarboxy)-3-(3-quinolyl)

### Claim 2 (depends on 1)

A compound according to claim 1, having the formula:
or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof.

### Claim 3 (depends on 2)

A compound according to claim 2 having the formula:
or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof.

### Claim 4 (depends on 2)

A compound according to claim 2 having the formula:
or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof.

### Claim 5 (depends on 1)

A compound according to claim 1 or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof wherein T is a 14- or 15-membered macrolide connected via a macrocyclic ring carbon atom.

### Claim 6 (depends on 1)

A compound according to claim 1 or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof wherein G is B′.

### Claim 7 (depends on 6)

A compound according to claim 6 or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof wherein B′ is selected from the group consisting of: (a) an aryl group, (b) a heteroaryl group, (c) a biaryl group, and (d) a fused bicyclic or tricyclic unsaturated or aromatic ring system optionally containing one or more carbonyl groups and one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein each (a)-(d) optionally is substituted with one or more R11 groups.

### Claim 8 (depends on 6)

A compound according to claim 6 or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof wherein E is
(a) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
(b) a 3-10 membered saturated, unsaturated, or aromatic carbocycle,
(c) a —W-[3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur],
(d) a —W-[3-10 membered saturated, unsaturated, or aromatic carbocycle],
(e) —C(O)—, (f) —C(O)O—, (g) —C(O)NR4—, (h) —C(═NR4)—,
(i) —C(═NR4)O—, (j) —C(═NR4)NR4—, (k) —OC(O)—, (l) —OC(O)O—,
(m) —OC(O)NR4—, (n) —NR4C(O)—, (o) —NR4C(O)O—,
(p) —NR4C(O)NR4—, (q) —NR4C(═NR4)NR4—, (r) —S(O)p—,
(s) —NR4S(O)2—, (t) —S(O)2NR4—, (u) —C(N—OR4)—, (v) —C(N—NR4R4)—,
(w) —C(S)NR4—, (x) —NR4C(S) (y) —C(S)O—, or (z) —OC(S)—, wherein
i) any of (a)-(d) immediately above optionally is substituted with one or more R5 groups; and
ii) W is selected from the group consisting of:
(aa) —OCO—, (bb) —OC(O)O—, (cc) —OC(O)NR4—, (dd) —NR4C(O)O—,
(ee) —OCNOR4—, (ff) —NR4—C(O)O—, (gg) —C(S)(NR4)—, (hh) —NR4—,
(ii) —OC(S)O—, (jj) —OC(S)NR4—, (kk) —NR4C(S)O—, (ll) —OC(S)NOR4—, (mm) —C(S)O—, (nn) —OC(S)—, (O)—C(O)—, (pp) —C(O)O—, (qq) —C(O)NR4—, (rr) —C(═NR4)—, (ss) —C(═NR4)O—, (tt) —C(═NR4)NR4—, (uu) —OC(O)—, (vv) —OC(O)O—, (ww) —OC(O)NR4—,
(xx) —NR4C(O)—, (yy) —NR4C(O)O—, (zz) —NR4C(O)NR4—, (aaa) —NR4C(═NR4)NR4—, (bbb) —S(O)p—, (ccc) —NR4S(O)2—, (ddd) —S(O)2NR4—, (eee) —C(N—OR4)—, (fff) —C(N—NR4R4)—, (ggg) —C(S)NR4—, or (hhh) —NR4C(S)—.

### Claim 9 (depends on 1)

A compound according to claim 1 or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof wherein
D is selected from the group consisting of (a) a C1-6 alkyl group, (b) a C2-6 alkenyl group, and (c) a C2-6 alkynyl group, wherein
i) 0-2 carbon atoms in any of (a)-(c) of D immediately above optionally is replaced by a moiety selected from the group consisting of O, S(O)p, and NR4,
ii) any of (a)-(c) of D immediately above optionally is substituted with one or more R5 groups; and
F is selected from the group consisting of (a) a single bond, (b) a C1-6 alkyl group, (c) a C2-6 alkenyl group, and (d) a C2-6 alkynyl group, wherein
i) 0-2 carbon atoms in any of (b)-(d) of F immediately above optionally is replaced by a moiety selected from the group consisting of O, S(O), and NR4;
ii) any of (b)-(d) of F immediately above optionally is substituted with one or more R5 groups; and
iii) any of (b)-(d) of F immediately above optionally is substituted with C1-6 alkyl-R5.

### Claim 10 (depends on 9)

A compound according to claim 9 or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof wherein
E is selected from the group consisting of:
(a) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
(b) a 3-10 membered saturated, unsaturated, or aromatic carbocycle,
(c) a —W-[3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur],
(d) a —W-[3-10 membered saturated, unsaturated, or aromatic carbocycle],
(e) —C(O)—, (f) —C(O)O—, (g) —C(O)NR4—, (h) —C(═NR4)—, (i) —C(═NR4)O—, (j) —C(═NR4)NR4—, (k) —OC(O)—, (l) —OC(O)O—,
(m) —OC(O)NR4—, (n) —NR4C(O)—, (o) —NR4C(O)O—, (p) —NR4C(O)NR4—, (q) —NR4C(═NR4)NR4—, (r) —S(O)p—, (s) —NR4S(O)2—, (t) —S(O)2NR4—, (u) —C(N—OR4)—,
(v) —CH2—, (w) —C(N—NR4R4)—, (x) —C(S)NR4, (Y) —NR4C(S)—, (Z) —C(S)O—, and
(aa) —OC(S)—, wherein
i) any of (a)-(d) immediately above optionally is substituted with one or more R5 groups; and
ii) W is selected from the group consisting of:
(aa) —OCO—, (bb) —OC(O)O—, (cc) —OC(O)NR4—,
(dd) —NR4C(O)O—, (ee) —OCNOR4—,
(ff) —NR4—C(O)O—, (gg) —C(S)(NR4)—, (hh) —NR4,
(ii) —OC(S)O—, (jj) —OC(S)NR4—, (kk) —NR4C(S)O—, (ll) —OC(S)NOR4—, (mm) —C(S)O—, (nn) —OC(S), (o) —C(O)—, (pp) —C(O)O—, (qq) —C(O)NR4—, (rr) —C(═NR4)—,
(ss) —C(═NR4)O—, (tt) —C(═NR4)NR4—, (uu) —OC(O)—, (vv) —OC(O)O—, (ww) —OC(O)NR4—, (xx) —NR4C(O)—, (yy) —NR4C(O)O—, (zz) —NR4C(O)NR4—, (aaa) —NR4C(═NR4)NR4—, (bbb) —S(O)p—, (ccc) —NR4S(O)2—, (ddd) —S(O)2NR4—, (eee) —C(N—OR4)—, (fff) —C(N—NR4R4)—, (ggg) —C(S)NR4—, and (hhh) —NR4C(S)—.

### Claim 11 (depends on 10)

A compound according to claim 10 or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof wherein
E is selected from the group consisting of:
(a) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and
(b) a 3-10 membered saturated, unsaturated, or aromatic carbocycle,
wherein (a) and (b) immediately above optionally is substituted with one more R5 groups.

### Claim 12 (depends on 9)

A compound according to claim 9 or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof wherein
E is selected from the group consisting of:
(a) —C(O)—, (b) —C(O)O—, (c) —C(O)NR4—, (d) —C(═NR4)—,
(e) —C(═NR4)O—, (f) —C(═NR4)NR4—, (g) —OC(O)—, (h) —OC(O)O—, (i) —OC(O)NR4—,
(j) —NR4C(O)—, (k) —NR4C(O)O—, (l) —NR4C(O)NR4—, (m) —NR4C(═NR4)NR4—, (n) —S(O)p—, (o) —NR4S(O)2—, (p) —S(O)2NR4—, (q) —C(N—OR4)—, (r) —CH2—, (s) —C(N—NR4R4)—, (t), —C(S)NR4, (u) —NR4C(S)—, (v) —C(S)O, and (w) —OC(S)—.

### Claim 13 (depends on 1)

A compound according to any one of according to claim 1, wherein T is:
or an N-oxide, pharmaceutically acceptable salt, ester or prodrug thereof,
wherein:
M is selected from the group consisting of:
(a) —C((O)—, (b) —CH(—OR114)—, (c) —NR114—CH2—, (d) —CH2—NR114—, (e) —CH(NR114R114)C(═NNR114R114)—, (g) —NR114—C(O)—, (h) —C(O)NR114—, (i) —C(═NR114)—, and (j) —CR115R115—, (k) —C(═NOR127)—;
R100 is selected from the group consisting of H and C1-6 alkyl;
R100 is selected from the group consisting of:
(a) H, (b) Cl, (c) F, (d) Br, (e) I, (f) —NR114R114, (g) —NR114C(O)R114, (h) —OR114,
(i) —OC(O)R114, (j) —OC(O)OR114, (k) —OC(O)NR114R114, (l) —O—C1-6 alkyl,
(m) —OC(O)—C1-6 alkyl, (n) —OC(O)O—C1-6 alkyl, (o) —OC(O)NR114—C1-6 alkyl,
(p) C1-6 alkyl, (q) C1-6 alkenyl, and (r) C1-6 alkynyl,
wherein any of (l)-(r) optionally is substituted with one or more R115 groups;
R102 is H;
R103 is selected from the group consisting of:
(a) H, (b) —OR114, (c) —O—C1-6 alkyl-R115, (d) —OC(O)R114,
(e) —OC(O)—C1-6 alkyl-R115, (f) —OC(O)OR114, (g) —OC(O)O—C1-6 alkyl-R115,
(h) —OC(O)NR114R114, (i) OC(O)NR114—C1-6 alkyl-R115, and
(j)
alternatively, R102 and R103 taken together form a carbonyl group;
alternatively, R101 and R103 taken together are a single bond between the respective carbons to which these two groups are attached thereby creating a double bond between the carbons to which R100 and R102 are attached;
alternatively, R101 and R103 taken together are an epoxide moiety;
R104 is selected from the group consisting of:
(a) H, (b) R114, (c) —C(O)R114, (d) —C(O)OR114 (e) —C(O)NR114R114, (f) —C1-6 alkyl-K—R114, (g) —C2-6 alkenyl-K—R114, and (h) —C2-6 alkynyl-K—R114;
alternatively R103 and R104, taken together with the atoms to which they are bonded, form:
K is selected from the group consisting of:
(a) —C(O)—, (b) —C(O)O—, (c) —C(O)NR114—, (d) —C(═NR114)—, (e) —C(═NR114)O—,
(f) —C(═NR114)NR114—, (g) —OC(O)—, (h) —OC(O)O—, (i) —OC(O)NR114—,
(j) —NR114C(O)—, (k) —NR114C(O)O—, (l) —NR114C(O)NR114—,
(m) —NR114C(═NR114)NR114—, and (o) —S(O)p—;
R105 is selected from the group consisting of:
(a) R114, (b) —OR114, (c) —NR114R114, (d) —O—C1-6 alkyl-R115, (e) —C(O)—R114,
(f) —C(O)—C1-6 alkyl-R115, (g) —OC(O)—R114, (h) —OC(O)—C1-6 alkyl-R115,
(i) —OC(O)O—R114, (j) —OC(O)O—C1-6 alkyl-R115, (k) —OC(O)NR
(l) —OC(O)NR114—C1-6 alkyl-R115, (m) —C(O)—C2-6 alkenyl-R115, and
(n) —C(O)—C2-6 alkynyl-R115;
alternatively, R104 and R105, taken together with the atoms to which they are bonded, form:
wherein
Q is CH or N, and R126 is —0R114, —NR114 or R114;
alternatively, R104 and R105, taken together with the atoms to which they are bonded, form:
wherein
i) R101 is as defined above;
ii) alternatively, R101 and R109 taken together form a carbonyl group;
iii) alternatively, R101 and R109 taken together form the group —O(CR116R116)uO—;
alternatively, R104 and R105, taken together with the atoms to which they are bonded, form:
i) R130 is —OH, ═C(O), or R114,
ii) R131 is —OH, ═C(O), or R114,
iii) alternatively, R130 and R131 together with the carbons to which they are attached form a 3-7 membered saturated, unsaturated or aromatic carbocyclic or heterocyclic ring which can optionally be substituted with one or more R114 groups;
R106 is selected from the group consisting of:
(a) —OR114, (b) —C1-6 alkoxy-R115, (c) —C(O)R114, (d) —OC(O)R114, (e) —OC(O)OR114,
(f) —OC(O)NR114R114, and (g) —NR114R114,
alternatively, R105 and R106 taken together with the atoms to which they are attached form a 5-membered ring by attachment to each other through a chemical moiety selected from the group consisting of:
(a) —OC(R115)2O—, (b) —OC(O)O—, (c) —OC(O)NR114—, (d) —NR114C(O)O—,
(e) —OC(O)NOR114—, (f) —NOR114—C(O)O—, (g) —OC(O)NNR114R114—,
(h) —NNR114R114—C(O)O—, (i) —OC(O)C(R115)2—, (j) —C(R115)2C(O)O—, (k) —OC(S)O—, (l) —OC(S)NR114—, (m) —NR114C(S)O—, (n) —OC(S)NOR114—, (o) —NOR114—C(S)O—,
(p) —OC(S)NNR114R114—, (q) —NNR114R114—C(S)O—, (r) —OC(S)C(R115)2—, and (s) —C(R115)2C(S)O—;
alternatively, M, R105, and R106 taken together with the atoms to which they are attached form:
wherein J is selected from the group consisting of O, S and NR114;
alternatively, M and R104 taken together with the atoms to which they are attached form:
R107 is selected from the group consisting of:
(a) H, (b) —C1-4 alkyl, (c) —C2-4 alkenyl, which can be further substituted with C1-12 alkyl or one or more halogens, (d) —C2-4 alkynyl, which can be further substituted with C1-12 alkyl or one or more halogens, (e) aryl or heteroaryl, which can be further substituted with C1-12 alkyl or one or more halogens, (f) —C(O)H, (g) —COOH, (h) —CN, (i) —COOR114, (j) —C(O)NR114R114, (k) —C(O)R114, and (l) —C(O)SR114, wherein
(b) is further substituted with one or more substituents selected from the group consisting of (aa) —OR114, (bb) halogen, (cc) —SR114, (dd) C1-12 alkyl, which can be further substituted with halogen, hydroxyl, C1-6 alkoxy, or amino, (ee) —OR114, (ff) —SR114, (gg) —NR114R114, (hh) —CN, (ii) —NO2, (jj) —NC(O)R114, (kk) —COOR114, (ll) —N3, (mm) ═N—O—R114, (nn) ═NR114, (oo) ═N—NR114R114, (pp) ═N—NH—C(O)R114, and (qq)═N—NH—C(O)NR114R114;
alternatively R106 and R107 are taken together with the atom to which they are attached to form an epoxide, a carbonyl, an olefin, or a substituted olefin, or a C3-C7 carbocyclic, carbonate, or carbamate, wherein the nitrogen of said carbamate can be further substituted with a C1-C6 alkyl;
R108 is selected from the group consisting of:
(a) C1-6 alkyl, (b) C2-6 alkenyl, and (c) C2-6 alkynyl,
wherein any of (a)-(c) optionally is substituted with one or more R114 groups;
R112 is selected from the group consisting of H, OH, and OR114;
R114, at each occurrence, independently is selected from the group consisting of:
(a) H, (b) C1-6 alkyl, (c) C2-6 alkenyl, (d) C2-6 alkynyl, (e) C6-10 saturated, unsaturated, or aromatic carbocycle, (f) 3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (g) —C(O)—C1-6 alkyl, (h) —C(O)—C2-6 alkenyl, (i) —C(O)—C2-6 alkynyl, (j) —C(O)—C6-10 saturated, unsaturated, or aromatic carbocycle, (k) —C(O)-3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (l) —C(O)O—C1-6 alkyl, (m) —C(O)O—C2-6 alkenyl, (n) —C(O)O—C2-6 alkynyl, (o) —C(O)O—C6-10 saturated, unsaturated, or aromatic carbocycle, (p) —C(O)O-3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (q) —C(O)NR116R116,
wherein any of (b)-(p) optionally is substituted with one or more R115 groups,
wherein one or more non-terminal carbon moieties of any of (b)-(d) optionally is replaced with oxygen, S(O)p, or —NR116;
alternatively, NR114R114 forms a 3-7 membered saturated, unsaturated or aromatic ring including the nitrogen atom to which the R114 groups are bonded and optionally one or more moieties selected from the group consisting of O, S(O)p, N, and NR118;
R115 is selected from the group consisting of:
(a) R117, (b) C1-8 alkyl, (c) C2-8 alkenyl, (d) C2-8 alkynyl, (e) C3-12 saturated, unsaturated, or aromatic carbocycle, and (f) 3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (b)-(f) optionally is substituted with one or more R117 groups;
R116 at each occurrence, independently is selected from the group consisting of:
(a) H, (b) C1-6 alkyl, (c) C2-6 alkenyl, (d) C2-6 alkynyl, (e) C3-10 saturated, unsaturated, or aromatic carbocycle, and (f) 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein one or more non-terminal carbon moieties of any of (b)-(d) optionally is replaced with oxygen, S(O)p, or —NR114, wherein any of (b)-(f) optionally is substituted with one or more moieties selected from the group consisting of:
(aa) carbonyl, (bb) formyl, (cc) F, (dd) Cl, (ee) Br, (ff) I, (gg) CN, (hh) N3, (ii)NO2, OR118, (kk) —S(O)pR118, (ll) —C(O)R118, (mm) —C(O)OR118, (nn) —OC(O)R118, (oo) —C(O)NR118R118, (pp) —OC(O)NR118R118, (qq) —C(═NR118)R118, (rr) —C(R118)(R118)OR118, (ss) —C(R118)2OC(O)R118, (tt) —C(R118)(OR118)(CH2)rNR118R118, (uu) NR118R118, (vv) —(NR118OR118, (ww) —NR118C(O)R118, (xx) —NR118C(O)OR118, (yy) —NR118C(O)NR NR118, (zz) —NR118S(O)rR118, (ab) —C(OR118)(0R118)R118, (ac) —C(R118)2NR118R118, (ad) ═NR118, (ae) —C(S)NR118R118, (af) —NR118C(S)R118, (ag) —OC(S)NR118R118, (ah) —NR118C(S)OR118, (ai) —NR118C(S)NR118R118, (aj) —SC(O)R118, (ak) C1-8 alkyl, (al) C2-8 alkenyl, (am) C2-8 alkynyl, (an) C1-8 alkoxy, (ao) C1-8 alkylthio, (ap) C1-8 acyl, (aq) saturated, unsaturated, or aromatic C3-10 carbocycle, and (ar) saturated, unsaturated, or aromatic 3-10 membered heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
alternatively, NR116R116 forms a 3-10 membered saturated, unsaturated or aromatic ring including the nitrogen atom to which the R116 groups are attached and optionally one or more moieties selected from the group consisting of O, S(O)p, N, and NR118;
alternatively, CR116R116 forms a carbonyl group;
R117, at each occurrence, is selected from the group consisting of:
(a) H, (b) ═O, (c) F, (d) Cl, (e) Br, (f) I, (g) (CR116R116)rCF3, (h) (CR116R116)rCN,
(i) (CR116R116)rNO2, (j) (CR116R116)rNR116(CR116R116)tR119, (k) (CR116R116)rOR119,
(l) (CR116R116)rS(O)p(CR116R116)tR119, (m) (CR116R116)rC(O)(CR116R116)tR119,
(n) (CR116R116)rOC(O)(CR116R116)tR119, (o) (CR116R116)rSC(O)(CR116R116)tR119,
(p) (CR116R116)rC(O)O(CR116R116)tR119, (q) (CR116R116)rNR116C(O)(CR116R116)tR119,
(r) (CR116R116)rC(O)NR116(CR116R116)tR119, (s) (CR116R116)rC(═NR116(CR116R116)rR119, (t) (CR116R116)rC(═NNR116R116)(CR116R116)tR119,
(u) (CR116R116)rC(═NNR116C(O)R116)(CR116R116)tR119, (v) (CR116R116)rC(═NOR119)(CR116R116)tR119, (w) (CR116R116)rNR116(CR116R116)tR119,
(x) (CR116R116)rOC(O)NR116(CR116R116)tR119,
(y) (CR116R116)rNR116C(O)NR116(CR116R116)tR119,
(z) (CR116R116)rNR116S(O)p(CR116R116)tR)119,
(aa) (CR116R116)rS(O)pNR116(CR116R116)tR119,
(bb) (CR116R116)rNR116S(O)pNR116(CR116R116)tR119, (cc) (CR116R116)rNR116R116,
(dd) C1-6 alkyl, (ee) C2-6 alkenyl, (ff) C2-6 alkynyl, (gg) (CR116R116)r—C3-10 saturated, unsaturated, or aromatic carbocycle, and (hh) (CR116R116)r-3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (dd)-(hh) optionally is substituted with one or more R119 groups;
alternatively, two R117 groups form —O(CH2)uO—;
R118 is selected from the group consisting of:
(a) H, (b) C1-6 alkyl, (c) C2-6 alkenyl, (d) C2-6 alkynyl, (e) C3-10 saturated, unsaturated, or aromatic carbocycle, (f) 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (g) —C(O)—C1-6 alkyl, (h) —C(O)—C1-6 alkenyl, (g) —C(O)—C1-6 alkynyl, (i) —C(O)—C3-10 saturated, unsaturated, or aromatic carbocycle, and (j) —C(O)-3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (b)-(j) optionally is substituted with one or more moieties selected from the group consisting of: (aa) H, (bb) F, (cc) Cl, (dd) Br, (ee) I, (ff) CN, (gg) NO2, (hh) OH, (ii) NH2, OD NH(C1-6 alky(l), (kk) N(C1-6 alky(l)2, (ll) C1-6 alkoxy, (mm) aryl, (nn) substituted aryl, (oo) heteroaryl, (pp) substituted heteroaryl, and (qq) C1-6 alkyl, optionally substituted with one or more moieties selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, F, Cl, Br, I, CN, NO2, and OH;
R119, at each occurrence, independently is selected from the group consisting of:
(a) R120, (b) C1-6 alkyl, (c) C2-6 alkenyl, (d) C2-6 alkynyl, (e) C3-10 saturated, unsaturated, or aromatic carbocycle, and (f) 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R120, at each occurrence, independently is selected from the group consisting of:
(a) H, (b) ═O, (c) F, (d) Cl, (e) Br, (f) I, (g) (CR116R116)rCF3, (h) (CR116R116)rCN,
(i) (CR116R116)rNO2, (j) (CR116R116)rNR116R116, (k) (CR116R116)rOR114,
(l) (CR116R116)rS(O)pR116, (m) (CR116R116)rC(O)R116, (n) (CR116R116)rC(O)OR116,
(o) (CR116R116)rOC(O)R116, (p) (CR116R116)rNR116C(O)R116,
(q) (CR116R116)rC(O)NR116R116, (r) (CR116R116)rC(═NR116)R116,
(s) (CR116R116)rNR116C(O)NR116R116, (t) (CR116R116)rNR116S(O)pR116,
(u) (CR116R116)rS(O)pNR116R116, (v) (CR116R116)rNR116S(O)pNR116R116,
(w) C1-6 alkyl, (x) C2-6 alkenyl, (y) C2-6 alkynyl, (z) (CR116R116)r—C3-10 saturated, unsaturated, or aromatic carbocycle, and (aa) (CR116R116)r-3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (w)-(aa) optionally is substituted with one or more moieties selected from the group consisting of R116, F, Cl, Br, I, CN, NO2, —OR116, —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, C1-6 alkoxy, C1-6 alkylthio, and C1-6 acyl;
R121, at each occurrence, independently is selected from the group consisting of:
(a) H, (b) —OR118, (c) —O—C1-6 alkyl-OC(O)R118, (d) O—C1-6 alkyl-OC(O)OR118,
(e) —O—C1-6 alkyl-OC(O)NR118R118, (f) —O—C1-6 alkyl-C(O)NR118R118, (g) —O C1-6 alkyl-NR118C(O)R118, (h) —O—C1-6 alkyl-NR118C(O)OR118, (i) —O—C1-6 alkyl-NR118C(O)NR118R118, (j) —O—C1-6 alkyl-NR118C(═N(H)NR118R118, (k) —O—C1-6 alkyl-S(O)pR118, (l) —O—C2-6 alkenyl-OC(O)R118, (m) —O—C2-6 alkenyl-OC(O)OR118, (n) —O—C2-6 alkenyl-OC(O)NR118R118, (o) —O—C2-6 alkenyl-C(O)NR118R118, (p) —O—C2-6 alkenyl-NR118C(O)R118, (q) —O—C2-6 alkenyl-NR118C(O)OR118, (r) —O—C2-6 alkenyl-NR118C(O)NR118R118, (s) —O—C2-6 alkenyl-NR118C(═N(H)NR118R118,
(t) —O—C2-6 alkenyl-S(O)pR118,
(u) —O—C2-6 alkynyl-OC(O)R118, (v) —O—C2-6 alkynyl-OC(O)OR118,
(w) —O—C2-6 alkynyl-OC(O)NR118R118, (x) —O—C2-6 alkynyl-C(O)NR118R118, (y) —O—C2-6 alkynyl-NR118C(O)R118, (z) —O—C2-6 alkynyl-NR118C(O)OR118, (aa) —O—C2-6 alkynyl-NR118C(O)NR118R118,
(bb) —O—C2-6 alkynyl-NRH8C(═N(H)NR118R118, (cc) —O—C2-6 alkynyl-S(O)pR118, and
(dd) —NR118R118;
alternatively, two R121 groups taken together form ═O, ═NOR118, or ═NNR118R118;
R124, at each occurrence, independently is selected from the group consisting of:
(a) H, (b) F, (c) Cl, (d) Br, (e) I, (f) CN, (g) —OR114, (h) —NO2, (i) —NR114R114, (j) C1-6 alkyl, (k) C1-6 acyl, and (l) C1-6 alkoxy;
R109 is H or F;
R127 is R114, a monosaccharide or disaccharide (including amino sugars and halo sugar(s)), —(CH2)n—(O—CH2CH2—)m—O(CH2)pCH3, or —(CH2)n—(O—CH2CH2—)m—OH;
R128 is R114;
R129 is R114;
R110 is R114;
alternatively, R109 and R110 taken together with the carbons to which they are attached form:
alternatively, R128 and R129 together with the carbons to which they are attached form a 3-6 membered saturated, unsaturated or aromatic carbocyclic or heterocyclic ring which optionally be substituted with one or more R114 groups;
m, at each occurrence is 0, 1, 2, 3, 4, or 5;
n, at each occurrence is 1, 2, or 3.

### Claim 14 (depends on 13)

A compound according to claim 13, wherein T is a macrolide selected from the group consisting of:
or an N-oxide pharmaceutically acceptable salt, ester, or prodrug thereof.

### Claim 15 (depends on 13)

A compound according to claim 13, wherein T is a macrolide selected from the group consisting of:
or an N-oxide pharmaceutically acceptable salt, ester, or prodrug thereof.

### Claim 16 (depends on 13)

A compound according to claim 13, wherein T is a macrolide selected from the group consisting of:
or an N-oxide pharmaceutically acceptable salt, ester, or prodrug thereof.

### Claim 17 (depends on 1)

A compound according to claim 1, wherein T is a macrolide selected from the group consisting of T1, T2, T3, T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, and T33:
or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof.

### Claim 18

A compound having the structure corresponding to any one of the structures listed in Table 1 or 13, or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method for treating or preventing a disease state in a mammal comprising administering to a mammal in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof.
